Oruka Therapeutics, Inc. (ORKA)
Summary
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Oruka Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 26 | $1,275 | $2,509.26 | $1,234.26 | 96.8% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 2,332 | $221,940 | $230,448.24 | $8,508.24 | 3.83% |
| NA Nizar Araji National Bank Of Canada /FI/ | 5 | $462.45 | $494.1 | $31.65 | 6.84% |
| BG Bart Gancher Intech Investment Management LLC | 11,763 | $184,298.77 | $1.16M | $978,120.89 | 530.73% |
| BH Brian Hunsaker Iron Gate Global Advisors LLC | 2,750 | $261,718 | $305,360 | $43,642 | 16.68% |
Oruka Therapeutics, Inc. (ORKA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oruka Therapeutics, Inc. ever had a stock split?
Oruka Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lawrence Otto Klein CEO | NASDAQ (NMS) Exchange | 687604108 CUSIP |
| US Country | 68 Employees | 29 Aug 2024 Last Dividend | 3 Sep 2024 Last Split | - IPO Date |
Overview
Oruka Therapeutics, Inc. is an innovative biotechnology company primarily engaged in the development of cutting-edge monoclonal antibody therapeutics. The focus of their research and development efforts lies in addressing the needs of patients suffering from Psoriasis (PsO) and other Immune and Inflammation (I&I) indications. With its headquarters strategically located in Menlo Park, California, Oruka Therapeutics is at the forefront of biotechnological advances, leveraging its strategic location in one of the world’s leading biotech hubs to facilitate collaboration, innovation, and growth.
Products and Services
The core offerings of Oruka Therapeutics, Inc. include a promising pipeline of monoclonal antibody therapeutic products:
- ORKA-001 - This novel monoclonal antibody is designed specifically to target and mitigate the underlying causes of Psoriasis (PsO). By focusing on a key pathway involved in the immune and inflammatory response, ORKA-001 aims to offer a targeted and effective treatment option for patients suffering from PsO, potentially improving their quality of life significantly.
- ORKA-002 - As another significant product in Oruka Therapeutics' pipeline, ORKA-002 represents the company’s commitment to expanding its range of therapeutic solutions. While the specific details of ORKA-002’s mechanism of action and target indications beyond “other I&I indications” are not explicitly detailed, it signifies the company’s ongoing efforts in addressing a broad spectrum of immune and inflammatory diseases, thereby underscoring Oruka Therapeutics’ dedication to pioneering in the field of monoclonal antibody therapies.
